Citigroup’s Intensity Therapeutics INTS Stock Holding History
Bought
Maintained
Sold
Other funds holding INTS
Citigroup's INTS Position: Q3 2026 in Review
Citigroup opened a new position in Intensity Therapeutics (INTS) in Q3 2026: 234 shares worth $789. The stake represents ﹤0.01% of the portfolio and ranks #5559 among its holdings. This is a return to the name: Citigroup previously reported a position in INTS as recently as Q4 2025.
Citigroup first reported a position in INTS in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.8K in Q3 2025. 8 funds tracked by Wall St. Rank hold INTS as of Q3 2026.
- Citigroup held 234 shares of Intensity Therapeutics worth $789 as of Q3 2026.
- Intensity Therapeutics was a new Citigroup position in Q3 2026.
- Intensity Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5559 holding.
- Citigroup first reported a position in Intensity Therapeutics in Q3 2025 and has held it in 3 quarters since.
- Citigroup's Intensity Therapeutics position peaked at $10.8K in Q3 2025.
- 8 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.